| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gary Remington | Q80160585 |
| P2860 | cites work | Dopamine D4 receptors elevated in schizophrenia | Q24318936 |
| Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine | Q24319813 | ||
| Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis | Q24645193 | ||
| Antipsychotic medication adherence: is there a difference between typical and atypical agents? | Q28214337 | ||
| Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia | Q28320367 | ||
| Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes | Q28375923 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. | Q30501297 | ||
| Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis | Q32068772 | ||
| Atypical antipsychotics and hyperglycaemia | Q32114302 | ||
| A comparative review of new antipsychotics | Q33606079 | ||
| The role of typical and atypical antipsychotic medications in the management of agitation and aggression | Q33642816 | ||
| Management strategies for the treatment of schizophrenia | Q33662363 | ||
| Atypical antipsychotics: are some more atypical than others? | Q33831594 | ||
| The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia | Q33867448 | ||
| Expected incidence of tardive dyskinesia associated with atypical antipsychotics. | Q33876490 | ||
| Measuring neuropsychological change in schizophrenia with novel antipsychotic medications | Q33877837 | ||
| The neuroleptics: a historical survey | Q68161667 | ||
| Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme | Q68161670 | ||
| Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values | Q69374550 | ||
| Pharmacology of neuroleptics in use in the United States | Q69866742 | ||
| The neuroleptic threshold as a marker of minimum effective neuroleptic dose | Q69884359 | ||
| The dopamine D4 receptor in schizophrenia: an update | Q71204057 | ||
| Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial | Q71607775 | ||
| Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder | Q71779823 | ||
| Further evidence of a dose-response threshold for haloperidol in psychosis | Q71933589 | ||
| A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients | Q72079402 | ||
| Long-term high-dose neuroleptic treatment: who gets it and why? | Q72228960 | ||
| Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors | Q72231713 | ||
| Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial | Q72659567 | ||
| Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials | Q72691613 | ||
| Atypical antipsychotics | Q73250709 | ||
| The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group | Q73437458 | ||
| The new antipsychotics, and their potential for early intervention in schizophrenia | Q74191791 | ||
| Second generation antipsychotics | Q74521282 | ||
| Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics | Q77352700 | ||
| A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia | Q77805002 | ||
| Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia | Q78170727 | ||
| Antipsychotic agents and QT changes. | Q33877850 | ||
| Atypical antipsychotics: mechanism of action. | Q33957716 | ||
| Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride | Q33959951 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Cardiac effects of antipsychotic medications | Q34237908 | ||
| Antipsychotic-induced weight gain: a review of the literature | Q34247423 | ||
| Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain | Q34327236 | ||
| Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia | Q34373489 | ||
| The changing roles and targets for animal models of schizophrenia | Q34463396 | ||
| Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient | Q34463410 | ||
| Management of treatment resistance in schizophrenia | Q34463421 | ||
| Influence of novel and conventional antipsychotic medication on subjective quality of life | Q34464310 | ||
| Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors | Q34467237 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? | Q34515214 | ||
| Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. | Q34549699 | ||
| Glutamate receptor dysfunction and schizophrenia | Q34719075 | ||
| Risperidone in the treatment of schizophrenia | Q34719470 | ||
| The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. | Q34719726 | ||
| Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia | Q34756417 | ||
| The third dopamine receptor (D3) as a novel target for antipsychotics | Q35251017 | ||
| Schizophrenia and the D1 receptor: focus on negative symptoms | Q35264032 | ||
| Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 | Q35275118 | ||
| Clozapine. A novel antipsychotic agent | Q36485618 | ||
| D1and D2and D3 | Q36534005 | ||
| Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group | Q36863074 | ||
| Clinically relevant differences between antipsychotic compounds | Q37604211 | ||
| Biochemical and behavioural properties of clozapine | Q38366717 | ||
| The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia | Q39461443 | ||
| Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses | Q39465776 | ||
| Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology | Q39631492 | ||
| The use of depot neuroleptics: clinical experience in the United States | Q40175188 | ||
| The potential benefits of serotonin receptor-specific agents. | Q40392176 | ||
| Survey on the pharmacodynamics of the new antipsychotic risperidone | Q40397376 | ||
| Multiple serotonin receptors: clinical and experimental aspects | Q40558564 | ||
| Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. | Q40624441 | ||
| Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action | Q40641921 | ||
| Serotonin receptors--where are they going? | Q40666689 | ||
| The use of high-dose antipsychotic medication | Q40676560 | ||
| Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials | Q40824415 | ||
| Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes | Q40893820 | ||
| Serotonin-dopamine interaction and its relevance to schizophrenia | Q40945989 | ||
| Glutamate pharmacology and the treatment of schizophrenia: current status and future directions | Q40972907 | ||
| Serotonin receptor specificity in anxiety disorders | Q40997085 | ||
| The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches | Q41086108 | ||
| Treatment-resistant schizophrenic patients | Q41123215 | ||
| Pharmacoeconomics of antipsychotic drug therapy | Q41123279 | ||
| Mechanisms of action of atypical antipsychotic drugs: a critical analysis | Q41232968 | ||
| The promise of new drugs for schizophrenia treatment | Q41441428 | ||
| The biological basis of schizophrenia: new directions. | Q41572980 | ||
| Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence | Q41682564 | ||
| Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine | Q42058566 | ||
| The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs | Q42191070 | ||
| Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors | Q42202596 | ||
| Predictors of acute dystonia in first-episode psychotic patients. | Q42282739 | ||
| D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects | Q42506008 | ||
| A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia | Q42940042 | ||
| New targets for antipsychotics | Q43265600 | ||
| Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients | Q43548197 | ||
| In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia | Q43555142 | ||
| A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia | Q43692964 | ||
| Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. | Q43873912 | ||
| Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia | Q43899475 | ||
| Significant dissociation of brain and plasma kinetics with antipsychotics | Q43937698 | ||
| D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory | Q45191426 | ||
| Defining treatment refractoriness in schizophrenia | Q45256751 | ||
| Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol | Q46238336 | ||
| Olanzapine: a novel atypical neuroleptic agent | Q46407614 | ||
| 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. | Q47863120 | ||
| Time course and biologic correlates of treatment response in first-episode schizophrenia | Q48298764 | ||
| Striatal enlargement in rats chronically treated with neuroleptic. | Q48361967 | ||
| PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. | Q48600255 | ||
| Hyperprolactinaemia induced by risperidone. | Q48698026 | ||
| N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. | Q48886935 | ||
| A historical perspective of clozapine. | Q53548188 | ||
| Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. | Q53929198 | ||
| An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. | Q54001868 | ||
| Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. | Q54014436 | ||
| Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups | Q56910149 | ||
| Are Striatal Dopamine D4 Receptors Increased in Schizophrenia? | Q61713961 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 275-284 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Journal of Psychiatry & Neuroscience | Q15814226 |
| P1476 | title | Understanding antipsychotic "atypicality": a clinical and pharmacological moving target | |
| P478 | volume | 28 |
| Q44550334 | A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events |
| Q30462828 | Animal models of schizophrenia. |
| Q26863343 | Antipsychotic dosing: found in translation |
| Q37139258 | Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway |
| Q36779793 | Arrestin-dependent but G-protein coupled receptor kinase-independent uncoupling of D2-dopamine receptors |
| Q37370296 | Asenapine effects in animal models of psychosis and cognitive function |
| Q48849610 | Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. |
| Q40226041 | Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. |
| Q46297168 | Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice |
| Q35618940 | D(2)-Dopamine receptors target regulator of G protein signaling 9-2 to detergent-resistant membrane fractions |
| Q33257720 | Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis |
| Q26745421 | Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies |
| Q33260941 | Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs |
| Q89599823 | Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? |
| Q22241430 | Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia |
| Q33853390 | Modern antipsychotic drugs: a critical overview |
| Q26746056 | Multiple Targeting Approaches on Histamine H3 Receptor Antagonists |
| Q33828080 | Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis |
| Q36812337 | Plasma membrane compartmentalization of D2 dopamine receptors |
| Q37661476 | Progress in defining optimal treatment outcome in schizophrenia |
| Q57066893 | Role of SREBPs in Liver Diseases: A Mini-review |
| Q43760941 | Sedative load among community-dwelling people aged 75 years and older: a population-based study |
| Q36371727 | Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms |
| Q26744805 | Treating Negative Symptoms in Schizophrenia: an Update |
| Q42671407 | Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification |
| Q26823906 | What does schizophrenia teach us about antipsychotics? |
Search more.